beclomethasone dipropionate + olodaterol + tiotropium

This drug is a fixed-dose combination of three active ingredients used for inhalation therapy in respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). The components are: - **Beclomethasone dipropionate**: an inhaled corticosteroid (ICS) that reduces airway inflammation. - **Olodaterol**: a long-acting beta2-adrenergic agonist (LABA) that acts as a bronchodilator by relaxing airway smooth muscle through selective activation of the beta2-adrenergic receptor, leading to increased airflow[2]. - **Tiotropium**: a long-acting muscarinic antagonist (LAMA) that blocks muscarinic receptors in the airways, resulting in bronchodilation. Triple therapy with ICS/LABA/LAMA combinations is used for maintenance treatment of COPD to improve lung function and reduce exacerbations. While several triple combination inhalers exist globally, there is no evidence from the search results or current regulatory databases that a fixed-dose product containing specifically beclomethasone dipropionate + olodaterol + tiotropium has been approved or marketed under any brand name as of June 2025. However, clinical studies and guidelines support the use of triple therapy regimens using these classes together[3][7].